Haisco：HSK46256 has received its first clinical trial approval.
HSK46256 is a novel drug independently developed by Haisco with full intellectual property rights for the treatment of advanced solid tumors. Preclinical study results have shown that HSK46256 demonstrates potential efficacy across multiple tumor cell lines and exhibits potent anti-tumor activity in homologous recombination repair deficiency models. It has the potential to be used for the treatment of cancers associated with homologous recombination repair deficiency, particularly those with BRCA mutations, such as breast cancer, ovarian cancer, and prostate cancer.
In addition, HSK46256 exhibits favorable brain penetration properties. In intracranial tumor efficacy models, it effectively inhibits intracranial tumor proliferation and prolongs animal survival. It is a small-molecule drug with significant development potential.
Buy HSK46256 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
